Alamar Biosciences (Nasdaq: ALMR) lifts Q2 revenue 82% and guides 2026 up 59%
Rhea-AI Filing Summary
Alamar Biosciences, Inc. reported strong growth for the quarter ended June 30, 2026. Total revenue was $29.4 million, up 82% from $16.2 million a year earlier. Instruments contributed $7.8 million, consumables $15.5 million, and services and other revenue $6.2 million, with consumable revenue rising 147% year-over-year on demand for multiplex panels. Gross margin improved to 60% from 53%, driven by manufacturing efficiencies and a revenue mix shift toward higher-margin consumables.
Operating expenses increased to $31.2 million, up 89% from $16.5 million, reflecting higher headcount, infrastructure, R&D investments and public company costs. Operating loss widened to $13.5 million from $7.9 million, and net loss was $13.2 million versus $7.0 million, with net loss per share of $(0.22) compared with $(0.62). Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million as of June 30, 2026. For full year 2026, the company forecasts revenue of $116–$120 million, representing 59% growth at the midpoint over 2025.
Positive
- Revenue grew 82% year-over-year in Q2 2026 to $29.4 million, with consumable revenue up 147% and services up 49%, indicating rapid commercial traction.
- Gross margin expanded to 60% from 53% in the prior-year quarter, aided by efficiencies and a mix shift toward higher-margin consumables.
- The company provided 2026 revenue guidance of $116–$120 million, implying 59% growth at the midpoint compared to 2025.
Negative
- Operating expenses rose 89% year-over-year in Q2 2026 to $31.2 million, outpacing revenue growth and pressuring profitability.
- Net loss increased to $13.2 million in Q2 2026 from $7.0 million a year earlier, reflecting higher operating costs and a loss on remeasurement of convertible notes.
- For the first half of 2026, net loss more than doubled to $34.5 million from $14.7 million in the prior-year period.
Filing Explained
The June 30 balance sheet shows zero convertible preferred stock and positive stockholders’ equity of $312,857 thousand.
Under Item 2.02, Alamar Biosciences furnished its financial results for the quarter ended
At
Compared with
8-K Event Classification
Key Figures
Key Terms
gross margin financial
stock-based compensation financial
operating lease right-of-use assets financial
warrant liabilities financial
convertible preferred stock financial
Earnings Snapshot
For full year 2026, revenue is expected to be in the range of $116 million to $120 million, representing growth of 59% at the midpoint of the range compared to 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Alamar Biosciences (ALMR) perform financially in Q2 2026?
What drove Alamar Biosciences (ALMR) revenue growth in Q2 2026?
What is Alamar Biosciences (ALMR) 2026 revenue guidance?
How did profitability metrics change for Alamar Biosciences (ALMR) in Q2 2026?
What is the cash position of Alamar Biosciences (ALMR) as of June 30, 2026?
How did stock-based compensation affect Alamar Biosciences (ALMR) in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 10, 2026, Alamar Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit number |
|
Description |
|
|
|
99.1 |
|
Press Release dated August 10, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Alamar Biosciences, Inc. |
|
|
|
|
Date: August 10, 2026 |
By: |
/s/ Justin McAnear |
|
|
Justin McAnear |
|
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
Exhibit 99.1
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
FREMONT, Calif.--August 10, 2026 (GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended June 30, 2026.
Recent Highlights
"We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year," said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. "With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters."
Second Quarter 2026 Financial Results
Revenue was $29.4 million for the second quarter of 2026, an 82% increase from $16.2 million for the corresponding prior-year period. Instrument revenue grew 35% to $7.8 million, from $5.8 million for the corresponding prior-year period, driven primarily by continued growth in new instrument placements. Consumable revenue grew 147% to $15.5 million, from $6.3 million for the corresponding prior-year period, driven primarily by strong demand for multiplex panels. Services and other revenue grew 49% to $6.2 million, from $4.1 million for the corresponding prior-year period.
Gross margin was 60% for the second quarter of 2026, as compared to 53% for the corresponding prior-year period. The increase in gross margin was primarily driven by manufacturing efficiencies for consumables and a favorable shift in mix toward high-margin consumables.
Operating expenses were $31.2 million for the second quarter of 2026, an 89% increase from $16.5 million for the corresponding prior-year period. The year-over-year increase in operating expenses was primarily related to planned investments in headcount, infrastructure and R&D capabilities as well as incremental public company costs.
Operating loss was $13.5 million for the second quarter of 2026, as compared to an operating loss of $7.9 million for the corresponding prior-year period. This includes $3.3 million of stock-based compensation for the second quarter of 2026, as compared to $0.7 million for the second quarter of 2025.
Net loss was $13.2 million for the second quarter of 2026 and higher than the $7.0 million net loss in the corresponding prior-year period.
Cash, cash equivalents, short-term investments and restricted cash were $256.3 million as of June 30, 2026.
2026 Guidance
Alamar Biosciences expects full year 2026 revenue to be in the range of $116 million to $120 million, representing growth of 59% at the midpoint of the range compared to full year 2025.
Webcast Information
Alamar Biosciences will host a conference call to discuss the second quarter 2026 financial results after market close on Monday, August 10, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investors.alamarbio.com/.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Forward Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ estimates for the full year 2026, its financial outlook, future plans and prospects, its ability to accelerate adoption of its platform and establish a new gold standard in protein detection and analysis, its anticipated sustained momentum in revenue growth from the recent launches of eMTBR-tau and the Immune 340 Panel, and Alamar Biosciences’ ability to grow its business. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Investor contact:
investors@alamarbio.com
Media contact:
media@alamarbio.com
Alamar Biosciences, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share data)
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||||||
|
|
|
2026 |
|
|
|
2025 |
2026 |
|
|
2025 |
|
|||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue |
|
|
$ |
|
23,269 |
|
|
$ |
|
12,040 |
|
|
$ |
|
44,610 |
|
|
$ |
|
21,209 |
|
Service and other revenue |
|
|
|
|
6,158 |
|
|
|
|
4,122 |
|
|
|
|
10,852 |
|
|
|
|
8,044 |
|
Total revenue(1) |
|
|
|
|
29,427 |
|
|
|
|
16,162 |
|
|
|
|
55,462 |
|
|
|
|
29,253 |
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of product revenue(2) |
|
|
|
|
9,858 |
|
|
|
|
6,489 |
|
|
|
|
19,668 |
|
|
|
|
11,860 |
|
Cost of service and other revenue(2) |
|
|
|
|
1,851 |
|
|
|
|
1,092 |
|
|
|
|
3,619 |
|
|
|
|
2,423 |
|
Total cost of revenue |
|
|
|
|
11,709 |
|
|
|
|
7,581 |
|
|
|
|
23,287 |
|
|
|
|
14,283 |
|
Gross profit |
|
|
|
|
17,718 |
|
|
|
|
8,581 |
|
|
|
|
32,175 |
|
|
|
|
14,970 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development(2) |
|
|
|
|
13,817 |
|
|
|
|
8,895 |
|
|
|
|
26,834 |
|
|
|
|
17,197 |
|
Selling, general and administrative(2) |
|
|
|
|
17,433 |
|
|
|
|
7,605 |
|
|
|
|
31,220 |
|
|
|
|
14,245 |
|
Total operating expenses |
|
|
|
|
31,250 |
|
|
|
|
16,500 |
|
|
|
|
58,054 |
|
|
|
|
31,442 |
|
Loss from operations |
|
|
|
|
(13,532 |
) |
|
|
|
(7,919 |
) |
|
|
|
(25,879 |
) |
|
|
|
(16,472 |
) |
Interest income, net |
|
|
|
|
1,875 |
|
|
|
|
630 |
|
|
|
|
2,414 |
|
|
|
|
1,416 |
|
Interest expense |
|
|
|
|
(224 |
) |
|
|
|
(48 |
) |
|
|
|
(447 |
) |
|
|
|
(94 |
) |
Loss on remeasurement of convertible notes |
|
|
|
|
(1,377 |
) |
|
|
|
— |
|
|
|
|
(9,971 |
) |
|
|
|
— |
|
Other (expense) income, net |
|
|
|
|
(34 |
) |
|
|
|
314 |
|
|
|
|
(270 |
) |
|
|
|
468 |
|
Net loss before income tax |
|
|
|
|
(13,292 |
) |
|
|
|
(7,023 |
) |
|
|
|
(34,153 |
) |
|
|
|
(14,682 |
) |
Provision for (benefit from) income taxes |
|
|
|
|
(93 |
) |
|
|
|
— |
|
|
|
|
371 |
|
|
|
|
— |
|
Net loss |
|
|
$ |
|
(13,199 |
) |
|
$ |
|
(7,023 |
) |
|
$ |
|
(34,524 |
) |
|
$ |
|
(14,682 |
) |
Net loss per share, basic and diluted |
|
|
$ |
|
(0.22 |
) |
|
$ |
|
(0.62 |
) |
|
$ |
|
(0.97 |
) |
|
$ |
|
(1.30 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
|
|
58,665,055 |
|
|
|
|
11,409,556 |
|
|
|
|
35,589,492 |
|
|
|
|
11,334,630 |
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||||||
(in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
Instruments |
|
$ |
|
7,788 |
|
|
$ |
|
5,773 |
|
|
$ |
|
15,169 |
|
|
$ |
|
9,919 |
|
Consumables |
|
|
|
15,481 |
|
|
|
|
6,267 |
|
|
|
|
29,441 |
|
|
|
|
11,290 |
|
Services |
|
|
|
6,158 |
|
|
|
|
4,122 |
|
|
|
|
10,852 |
|
|
|
|
7,794 |
|
Other revenue |
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
250 |
|
Total |
|
$ |
|
29,427 |
|
|
$ |
|
16,162 |
|
|
$ |
|
55,462 |
|
|
$ |
|
29,253 |
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||||||
(in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||||||
Cost of product revenue |
|
$ |
|
45 |
|
|
$ |
|
7 |
|
|
$ |
|
59 |
|
|
$ |
|
15 |
|
Cost of service and other revenue |
|
|
|
58 |
|
|
|
|
12 |
|
|
|
|
80 |
|
|
|
|
25 |
|
Research and development |
|
|
|
838 |
|
|
|
|
262 |
|
|
|
|
1,230 |
|
|
|
|
491 |
|
Selling, general and administrative |
|
|
|
2,339 |
|
|
|
|
399 |
|
|
|
|
3,378 |
|
|
|
|
768 |
|
Total stock-based compensation expense |
|
$ |
|
3,280 |
|
|
$ |
|
680 |
|
|
$ |
|
4,747 |
|
|
$ |
|
1,299 |
|
Alamar Biosciences, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)
|
|
June 30, |
|
|
December 31, |
|
||||
ASSETS |
|
|
|
|
|
|
|
|
||
Current Assets |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
132,969 |
|
|
$ |
|
30,002 |
|
Short-term investments |
|
|
|
117,083 |
|
|
|
|
— |
|
Accounts receivable |
|
|
|
20,344 |
|
|
|
|
12,753 |
|
Inventory |
|
|
|
45,409 |
|
|
|
|
38,482 |
|
Prepaid expenses and other current assets |
|
|
|
15,577 |
|
|
|
|
13,468 |
|
Total current assets |
|
|
|
331,382 |
|
|
|
|
94,705 |
|
Restricted cash |
|
|
|
6,254 |
|
|
|
|
4,907 |
|
Property and equipment, net |
|
|
|
13,358 |
|
|
|
|
10,498 |
|
Operating lease right-of-use assets |
|
|
|
35,798 |
|
|
|
|
26,130 |
|
Capitalized software, net |
|
|
|
1,605 |
|
|
|
|
1,988 |
|
Other assets—noncurrent |
|
|
|
2,578 |
|
|
|
|
1,764 |
|
Total assets |
|
$ |
|
390,975 |
|
|
$ |
|
139,992 |
|
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
||
Current Liabilities |
|
|
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
13,790 |
|
|
$ |
|
5,872 |
|
Accrued and other current liabilities |
|
|
|
11,893 |
|
|
|
|
15,759 |
|
Short-term operating lease liabilities |
|
|
|
2,277 |
|
|
|
|
2,099 |
|
Total current liabilities |
|
|
|
27,960 |
|
|
|
|
23,730 |
|
Long-term operating lease liabilities |
|
|
|
39,182 |
|
|
|
|
29,564 |
|
Warrant liabilities |
|
|
|
— |
|
|
|
|
247 |
|
Term debt |
|
|
|
9,947 |
|
|
|
|
9,810 |
|
Other noncurrent liabilities |
|
|
|
1,029 |
|
|
|
|
599 |
|
Total liabilities |
|
|
|
78,118 |
|
|
|
|
63,950 |
|
Convertible preferred stock |
|
|
|
— |
|
|
|
|
234,996 |
|
Stockholders’ equity (deficit) |
|
|
|
|
|
|
|
|
||
Founders preferred stock |
|
|
|
— |
|
|
|
|
— |
|
Common stock |
|
|
|
7 |
|
|
|
|
1 |
|
Additional paid-in capital |
|
|
|
516,288 |
|
|
|
|
9,892 |
|
Accumulated other comprehensive loss |
|
|
|
(139 |
) |
|
|
|
(72 |
) |
Accumulated deficit |
|
|
|
(203,299 |
) |
|
|
|
(168,775 |
) |
Total stockholders’ equity (deficit) |
|
|
|
312,857 |
|
|
|
|
(158,954 |
) |
Total liabilities, convertible preferred stock and stockholders' equity (deficit) |
|
$ |
|
390,975 |
|
|
$ |
|
139,992 |
|